Cargando…

Efficacy of low-dose risperidone in combination with sertraline in first-episode drug-naïve patients with schizophrenia: a randomized controlled open-label study

OBJECTIVE: Despite advances in pharmacology, the treatment of schizophrenia (SZ) remains a challenge due to relapse after antipsychotic discontinuation and multiple adverse effects of antipsychotics. We hypothesized that a low dose of risperidone in combination with sertraline would reduce serious a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lang, Xiaoe, Xue, Mei, Zang, Xiaocui, Wu, Fengchun, Xiu, Meihong, Zhang, Xiangyang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10318661/ https://www.ncbi.nlm.nih.gov/pubmed/37403159 http://dx.doi.org/10.1186/s12967-023-04272-7

Ejemplares similares

Effects of low-dose combined olanzapine and sertraline on negative and depressive symptoms in treatment-resistant outpatients with acute exacerbated schizophrenia
por: Lang, Xiaoe, et al.
Publicado: (2023)

Association between Changes in Total Antioxidant Levels and Clinical Symptom Improvement in Patients with Antipsychotic-Naïve First-Episode Schizophrenia after 3 Months of Risperidone Monotherapy
por: Wang, Keqiang, et al.
Publicado: (2022)

Obesity, antioxidants and negative symptom improvement in first-episode schizophrenia patients treated with risperidone
por: Gao, Zhiyong, et al.
Publicado: (2023)

Antioxidant Enzymes and Weight Gain in Drug-naive First-episode Schizophrenia Patients Treated with Risperidone for 12 Weeks: A Prospective Longitudinal Study
por: Liu, Haixia, et al.
Publicado: (2022)

The association between BDNF levels and risperidone-induced weight gain is dependent on the BDNF Val66Met polymorphism in antipsychotic-naive first episode schizophrenia patients: a 12-week prospective study
por: Liu, Jiahong, et al.
Publicado: (2021)

Genetic polymorphisms of BDNF on cognitive functions in drug-naive first episode patients with schizophrenia
por: Su, Xiuru, et al.
Publicado: (2021)

Glucose metabolism, hippocampal subfields and cognition in first-episode and never-treated schizophrenia
por: Xiu, Meihong, et al.
Publicado: (2023)

Comparison of Efficacy and Safety Between Low-Dose Ziprasidone in Combination With Sertraline and Ziprasidone Monotherapy for Treatment-Resistant Patients With Acute Exacerbation Schizophrenia: A Randomized Controlled Trial
por: Shi, Hui, et al.
Publicado: (2022)

Superoxide Dismutase, BDNF, and Cognitive Improvement in Drug-Naive First-Episode Patients With Schizophrenia: A 12-Week Longitudinal Study
por: Wu, Zhiwei, et al.
Publicado: (2021)

Neurotoxic Syndrome Developed after Taking Sertraline and Risperidone
por: Kim, Jeong-Min, et al.
Publicado: (2007)

Comparative study of clozapine versus risperidone in treatment-naive, first-episode schizophrenia: A pilot study
por: Sahni, Sukhtej, et al.
Publicado: (2016)

Smoking Affects the Patterns of Metabolic Disorders and Metabolic Syndrome in Patients With First-Episode Drug-Naive Schizophrenia: A Large Sample Study Based on the Chinese Han Population
por: Li, Zezhi, et al.
Publicado: (2021)

Effects of Risperidone on Cytokine Profile in Drug-Naïve First-Episode Psychosis
por: Noto, Cristiano, et al.
Publicado: (2015)

Relationship between TNF-α levels and psychiatric symptoms in first-episode drug-naïve patients with schizophrenia before and after risperidone treatment and in chronic patients
por: Lin, Chen, et al.
Publicado: (2021)

Sexual dimorphism in the relationship between Forkhead-Box P2 and BMI with cognitive deficits in schizophrenia
por: Yang, Mi, et al.
Publicado: (2022)

Glucose and Lipid Profiles Predict Anthropometric Changes in Drug-Naïve Adolescents Starting Treatment with Risperidone or Sertraline: A Pilot Study
por: Matera, Emilia, et al.
Publicado: (2022)

Association of telomere length and mitochondrial DNA copy number with risperidone treatment response in first-episode antipsychotic-naïve schizophrenia
por: Li, Zongchang, et al.
Publicado: (2015)

Metabolic biomarkers of risperidone-induced weight gain in drug-naïve patients with schizophrenia
por: Qiu, Yuying, et al.
Publicado: (2023)

Sex difference in association of symptoms and white matter deficits in first-episode and drug-naive schizophrenia
por: Lang, Xiao-E, et al.
Publicado: (2018)

Gabapentin adjunctive to risperidone or olanzapine in partially responsive schizophrenia: an open-label pilot study
por: Gabriel, Adel
Publicado: (2010)

An open-label, multicenter evaluation of the long-term safety and efficacy of risperidone in adolescents with schizophrenia
por: Pandina, Gahan, et al.
Publicado: (2012)

Plasma Lysophosphatidylcholine and Lysophosphatidylethanolamine Levels Were Associated With the Therapeutic Response to Olanzapine in Female Antipsychotics-naïve First-episode Patients With Schizophrenia
por: Liu, Jiahong, et al.
Publicado: (2021)

Sex difference in the interrelationship between TNF-α and oxidative stress status in first-episode drug-naïve schizophrenia
por: Zhu, Minghuan, et al.
Publicado: (2021)

N-Acetylaspartate Reduction in the Medial Prefrontal Cortex Following 8 weeks of Risperidone Treatment in First-Episode Drug-Naïve Schizophrenia Patients
por: Zong, Xiaofen, et al.
Publicado: (2015)

Striatum-related spontaneous coactivation patterns predict treatment response on positive symptoms of drug-naive first-episode schizophrenia with risperidone monotherapy
por: Zong, Xiaofen, et al.
Publicado: (2023)

RISPERIDONE IN SCHIZOPHRENIA
por: Agashe, Mohan, et al.
Publicado: (1999)

RISPERIDONE IN SCHIZOPHRENIA
por: Kumar, P.N. Suresh
Publicado: (1999)

Sex-Specific Association between Antioxidant Defense System and Therapeutic Response to Risperidone in Schizophrenia: A Prospective Longitudinal Study
por: Liu, Haixia, et al.
Publicado: (2022)

Efficacy of Adjunctive Sertraline for the Treatment of HIV-Associated Cryptococcal Meningitis: an open-label dose-ranging study
por: Rhein, Joshua, et al.
Publicado: (2016)

Prevalence and correlates of dyslipidemia in first-episode and drug-naïve major depressive disorder patients with comorbid abnormal glucose metabolism: Sex differences
por: Zhu, Quanfeng, et al.
Publicado: (2023)

Prevalence and clinical correlates of abnormal lipid metabolism in first-episode and drug-naïve patients with major depressive disorder with abnormal glucose metabolism
por: Zhu, Quanfeng, et al.
Publicado: (2023)

Short-term Effects of Risperidone Monotherapy on Spontaneous Brain Activity in First-episode Treatment-naïve Schizophrenia Patients: A Longitudinal fMRI Study
por: Hu, Mao-Lin, et al.
Publicado: (2016)

Neurometabolic correlates of 6 and 16 weeks of treatment with risperidone in medication-naive first-episode psychosis patients
por: Birur, Badari, et al.
Publicado: (2020)

The contribution of the cingulate cortex: treating depressive symptoms in first-episode drug naïve schizophrenia
por: Shen, Haoran, et al.
Publicado: (2023)

An Open-label Trial of Risperidone and Fluoxetine in Children with Autistic Disorder
por: Desousa, Avinash
Publicado: (2010)

Association of thyroid function with abnormal lipid metabolism in young patients with first-episode and drug naïve major depressive disorder
por: Hu, Jieqiong, et al.
Publicado: (2023)

Aripiprazole vs Risperidone Head-to-Head Effectiveness in First-Episode Non-Affective-Psychosis: A 3-Month Randomized, Flexible-Dose, Open-Label Clinical Trial
por: Garrido-Sánchez, Lucía, et al.
Publicado: (2022)

The Steady-State Comparative Bioavailability of Intramuscular Risperidone ISM and Oral Risperidone: An Open-Label, One-Sequence Study
por: Walling, David P, et al.
Publicado: (2021)

Effects of Risperidone and Paliperidone on Brain-Derived Neurotrophic Factor and N400 in First-Episode Schizophrenia
por: Wu, Rong-Qin, et al.
Publicado: (2018)

RISPERIDONE IN INDIAN PATIENTS WITH SCHIZOPHRENIA
por: Duggal, Harpreet S., et al.
Publicado: (1999)

Cannot write session to /tmp/vufind_sessions/sess_k1lld3djjlu7oj62sspgdjl9un